Antibacterial Agents TRIZ Cases

Novel quinolone derivatives incorporate a diphenyl ether substituent at the nitrogen position to expand structural diversity.

Engineered antibodies disrupt the PD-1/PD-L1 pathway to overcome immune tolerance and enhance T cell activation.

A gastroretentive formulation uses a composite matrix of gelling and effervescent agents to swell and float in the stomach.

Segmenting MPT63 and MPT64 domains creates a mediator that targets TBK1, p47phox, and HK2 to resolve unclear interaction mechanisms and boost vaccine efficacy.

Specific acylating agents accelerate oxime oxygen reaction to improve yield and reduce time for pyrazole carboxylic acid amide synthesis.

Segmenting the chemical process into distinct stages with intermediate purification steps improves purity and yield of antibacterial agents.

Benzodioxane compounds inhibit leukotriene A4 hydrolase, addressing the lack of effective inhibitors for asthma and cardiovascular disease management.

Peptide carriers transport hydrophobic antibiotics into bacteria while minimizing toxicity to mammalian cells.

Specific bacterial metabolites drive CD8+ T cell proliferation, addressing limited efficacy and adverse effects in current microbiota modulation approaches.

Cationic steroid antimicrobials resolve the trade-off between infection control and healing speed by modulating inflammatory responses for faster closure.

Bac-FRP-4 bacteriophage targets and destroys ETBF cells, avoiding broad-spectrum antibiotic side effects.

Thiol-yne synthesis creates cationic amino lipids to transfect primary cells without chromatography.

Local gene therapy delivers TLR5 and flagellin to tumor cells, resolving systemic activation limits.

A culture medium using plant peptone and protoporphyrin IX to produce polyribosyl phosphate.

Novel mucin-type glycoprotein isolated from jellyfish tissue via salt solution extraction and centrifugal separation.

C3 inhibitors block complement activation to reduce Porphyromonas gingivalis levels, preventing periodontitis and systemic inflammation.

Bivalent Smac mimetics overcome peptide instability by merging binding units to inhibit IAPs and sensitize tumors.

Leukotoxin eliminates pathologically activated leukocytes to treat inflammatory disorders while sparing healthy cells.

A segmented immunostimulatory composition separates complexed adjuvant mRNA from free antigen mRNA to enable efficient translation.

Fused imidazole purine derivatives inhibit human TNFα binding with high potency.

VQATQSNQHTPR peptide overcomes cancer immune suppression by boosting effector T cells and anti-cancer cytokines.

Deuterated ambroxol resists CYP3A4 metabolism to extend plasma half-life and treat drug-resistant tuberculosis.

CECT 8800 strain resolves infection recurrence by maintaining stable pH levels against commercial product resistance.

Plant extracts reduce tellurite ions to tellurium nanoparticles, eliminating toxic byproducts from traditional synthesis methods.

Humanized antibodies targeting the Neisseria gonorrhoeae 2C7 epitope eliminate the human anti-mouse antibody response, enabling safe repeat dosing.

Anionic latex encapsulates active ingredients during emulsion polymerization to create a sustained release reservoir.

L,D-transpeptidase inhibitors disrupt 3→3 cross-linkages in the bacterial cell wall to enhance antibiotic susceptibility.

Vaccine composition comprising attenuated Staphylococcus aureus enterotoxin and cytotoxin proteins provides effective immunity against bovine mastitis.

Compounds with a 7-atom nitrogenated ring in fused tri-heterocycles inhibit PARP activity, expanding structural diversity beyond standard 6-ring inhibitors.

Polar lipid liposomes encapsulate anti-inflammatory agents, reducing nasal mucosa irritation while maintaining therapeutic efficacy.

A topical composition uses lactic acid to lower skin and nail pH, creating an environment that inhibits fungal growth.

A fixed-dose pharmaceutical composition combines rifabutin, clarithromycin, and clofazimine in specific ratios to optimize serum levels.

A synthetic peptide complex reduces surface tension in pulmonary surfactant formulations.

Replacing pivaloyloxymethyl groups with alternative esters eliminates tissue carnitine depletion while maintaining oral exposure.

Dynamic kinetic resolution synthesizes monobactam intermediates through asymmetric catalytic reduction, eliminating nitrogen protection steps that lower yield.

Immunostimulatory ligands expand Th17 cells to overcome T regulatory cell suppression in cancer treatments.

Substituted phthalocyanine dyes shift activation wavelengths above 670 nm, enabling deep tissue penetration and selective tumor accumulation.

A segmented anti-endotoxin polypeptide uses distinct functional domains to neutralize endotoxins while maintaining antibacterial activity and high salt resistance.

Segmenting intensive cream and maintenance powder phases reduces fungal resistance while preserving immune function.

A hypoallergenic footwear design uses a permeable structure to manage water vapor transmission and limit allergen concentrations in materials.

A tetravalent Shigella bioconjugate vaccine links four serotype antigens to Exoprotein A using oligosaccharyltransferases for reproducible manufacturing.

A polysaccharide-protein conjugate forms a covalent oxime bond using an anhydro 3-deoxy-D-manno-octulsonic acid moiety.

A vaccine uses a coiled peptide structure to modulate immune responses via directed adjuvants.

Pharmacophore models guide synthesis of compounds that selectively inhibit bacterial LpxA and ACP interactions, sparing human cells.

A self-healing hydrogel formed from antibacterial polypeptide polymerization provides injectable wound coverage with hemostatic properties.

Boron-based prodrugs replace phenolic hydroxyl groups with boron-containing moieties to enhance oral bioavailability.

Ethanol and peroxide penetrate biofilms while EDTA chelates metal ions, resolving antibiotic resistance caused by protective barriers.